Cybin announces phase 2 cohort 5 dosing completion of cyb003 in major depressive disorder

- cohort 5 completed with no safety or tolerability issues, final cohort 6 is recruiting with dosing expected to commence shortly - - phase 2 efficacy data for cyb003 in major depressive disorder expected in q3/q4 2023 - - u.s. food and drug administration ("fda") submission of cyb003 phase 1/2a data for pivotal studies expected following topline efficacy data readout - toronto , july 24, 2023 /prnewswire/ - cybin inc. (nyse american: cybn) (neo: cybn) ("cybin"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that its phase 2 trial evaluating cyb003, an investigational proprietary deuterated analog of psilocybin for the potential treatment of major depressive disorder ("mdd"), has completed dosing in cohort 5 with no serious adverse events or other adverse events that may preclude continued dosing.  the completed cohorts 4 and 5 evaluated two 12mg doses of cyb003, and recruitment is underway to commence dosing for cohort 6, the final cohort in the phase 2 portion of the study.
CYBN Ratings Summary
CYBN Quant Ranking